​​​Copyright © 2016 RiboCor, Inc. All rights reserved.     RiboCor, Inc. • 7077 Northland Circle North • Suite 100 • Minneapolis • MN • 55428 • Phone: 866-246-3637 • Email: Info@ribocor.com

Treatment of Fibromyalgia

Persistent chronic fatigue and diffuse migratory pain are the two most common symptoms of fibromyalgia. Current drug therapies target neuropathic pain but none effectively address the debilitating chronic fatigue. Preliminary studies in patients have shown depleted ATP levels in some skeletal muscle tender points. These tender points are a hallmark diagnostic of fibromyalgia. Initial open label clinical studies have demonstrated that Ribose significantly reduces clinical symptoms, particularly chronic fatigue, in patients suffering from fibromyalgia. RiboCor has conducted a small multi-site, double-blind, placebo-controlled study assessing the effect of Ribose on the fatigue experienced by fibromyalgia patients and shown some initial positive effects. Subsequent, more thorough, clinical characterization of Ribose pharmacokinetics revealed that a higher dose and a modified dose regimen should be employed, thus increasing the clinical benefit to patients.

Treatment of Cardiovascular Diseases

Normal cardiac function requires a steady supply of ATP both at rest and under the stress of exercise. Depleted myocardial ATP levels have been documented in several preclinical models of myocardial ischemia and heart failure. Administration of Ribose under those conditions helps replenish ATP and phosphocreatine, another essential high energy phosphate compound. Using 31P magnetic resonance imaging, diminished high energy phosphates also have been documented in patients with coronary artery disease during exercise induced stress. In several small clinical studies, Ribose has been shown to improve cardiopulmonary function in patients with coronary artery disease or heart failure. Based on these findings, RiboCor has conducted additional preclinical work to refine the dose and dose regimen and aid in the selection of optimal clinical endpoints to be followed by the design and execution of a clinical proof-of-concept study in heart failure patients.

RiboCor is also examining further clinical research into the use of Ribose for the treatment of atrial fibrillation and for recovery from coronary artery bypass graft (CABG) surgery,  pulmonary hypertension, myocardial infarction and chronic ischemia.

RiboCor is developing pharmaceutical products, based on its proprietary applications and technologies, focusing in the areas of cardiovascular medicine and the treatment of fibromyalgia.

RiboCor Pharmaceuticals